Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...

Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...

The results from the SUMMIT trial of tirzepatide in obese ... In the 731-patient SUMMIT study, participants were randomly assigned to either tirzepatide at a dose of between 2.5mg and 15mg per ...

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

“The investigators in the trials of the participants assigned to liraglutide and tirzepatide did not provide additional information about the causes of deaths and their relation to the trial ...

Eli Lilly’s diabetes and obesity therapy tirzepatide could find a use as a treatment for obstructive sleep apnoea (OSA) after hitting the mark in a pair of phase 3 trials. OSA is a prevalent ...

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...